A Randomized, Observer-Blinded, Placebo-Controlled Study on the Safety and Efficacy of Twice Daily Application of SM-030 Gel 0.64% Vs. SM-030 Gel 0.08% Vs. Placebo Gel in Adults With Melasma
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Melanosis
- Focus Therapeutic Use
- Sponsors DermBiont
Most Recent Events
- 19 Aug 2024 Planned End Date changed from 1 Jul 2025 to 1 Oct 2025.
- 19 Aug 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Apr 2025.
- 06 Jun 2024 Status changed from planning to recruiting.